Exosome draws $5M in financing for molecular Dx work

Exosome Diagnostics has raised $5 million out of a targeted $6 million offering, GenomeWeb reports. The company will likely use the funding, secured from two investors, to advance development of its molecular diagnostics test for cancer and other diseases. Exosome is also focused on the companion diagnostic space. Story (subs. req.)

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.